Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Summary

The purpose of this study is to investigate the safety and efficacy of giving atezolizumab combined with bevacizumab in patients with stage 4 epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) whose cancer has gotten worse while receiving osimertinib.

Timeline

Start

2020-07-09

Primary completion

2022-11-13

Completion

2023-06-15

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual”

Drugs

Indications